Healthpeak Properties
DOC
$22.06
-1.87%
Healthpeak Properties is a real estate investment trust (REIT) that owns a diversified healthcare portfolio of approximately 700 properties, primarily medical office and life science assets, along with senior housing and skilled nursing facilities. As a leading healthcare REIT, it distinguishes itself through its scale and diversification across multiple healthcare real estate segments. The current investor narrative centers on the company's strong operational momentum, driven by robust demand for life science and medical office space, as well as improving fundamentals in its senior housing portfolio, which have fueled a significant stock price rally over the past year.…
DOC
Healthpeak Properties
$22.06
DOC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Healthpeak Properties's 12-month outlook, with a consensus price target around $22.39 and implied upside of +1.5% versus the current price.
Average Target
$22.39
0 analysts
Implied Upside
+1.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$17 - $29
Analyst target range
The stock is covered by 19 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 2.41 (where 1 is strong buy and 5 is sell). The average target price is $22.34, implying a negligible 0.3% upside from the current price of $22.27. The consensus leans bullish, but the target price suggests limited near-term upside. The target range spans from a low of $17.00 to a high of $29.00, representing a wide spread of 70.6% from low to high. The high target of $29.00 implies 30.3% upside and likely assumes continued strong performance in life sciences and senior housing. The low target of $17.00 implies 23.7% downside and may reflect risks such as rising interest rates or occupancy declines. Recent ratings show a mix of neutral and bullish stances, with Barclays downgrading from Overweight to Equal Weight in July 2026, while Mizuho and BMO Capital maintain Outperform. The wide target spread indicates high uncertainty among analysts, which is typical for REITs sensitive to interest rate changes.
Bulls vs Bears: DOC Investment Factors
Healthpeak Properties presents a mixed picture: strong revenue growth, improving profitability, and positive momentum are countered by extreme valuation metrics and limited near-term upside. The bull case rests on continued operational strength and favorable healthcare real estate demand, while the bear case highlights the stretched P/E and potential earnings headwinds. The most critical tension is whether the company can sustain its earnings growth to justify the current valuation, or if a correction is imminent. Currently, the evidence slightly favors the bulls given the solid fundamentals and analyst support, but the risk/reward is balanced.
Bullish
- Strong Revenue Growth: Revenue grew 7.1% YoY to $753M in Q1 2026, driven by solid demand across medical office and life science segments. This consistent growth supports stable cash flows for the REIT.
- Improving Profitability: Net income surged 352% YoY to $194M in Q1 2026, with net margin expanding to 25.7% from 6.1% a year ago. Operating margin of 15.5% indicates efficient cost management.
- Strong Momentum Near 52-Week High: The stock is trading at $22.27, just 2.2% below its 52-week high of $22.77, with a 1-year return of +18.0% outperforming the S&P 500's +16.5%. Recent 3-month gain of 35.5% reflects accelerating bullish sentiment.
- Analyst Consensus Buy: With 19 analysts covering the stock, the consensus recommendation is 'buy' and the mean score is 2.41 (1=strong buy, 5=sell). The average target price of $22.34 is near the current price, suggesting limited downside.
Bearish
- Extremely High Trailing P/E: The trailing P/E of 160.8x is extremely high, even for a REIT, and far above its historical range. This implies the market is pricing in aggressive future growth that may not materialize.
- Negative Forward P/E: The forward P/E is -148.5x due to estimated negative EPS, indicating expected near-term earnings weakness. This unusual metric signals high uncertainty and potential earnings volatility.
- Limited Upside to Analyst Target: The average analyst target of $22.34 implies only 0.3% upside from the current price of $22.27. With the stock near its 52-week high, the risk/reward is skewed to the downside.
- High Debt-to-Equity Ratio: The debt-to-equity ratio of 1.39 indicates moderate leverage, which could pressure earnings if interest rates remain elevated. Interest expense of $87.3M in Q1 2026 consumes a significant portion of operating income.
DOC Technical Analysis
The stock is in a sustained uptrend, with a 1-year price change of +18.0%, significantly outperforming the S&P 500's +16.5% over the same period. The current price of $22.27 sits at 97.8% of its 52-week range ($15.70–$22.77), indicating strong momentum and near-term overextension but also reflecting bullish sentiment. This positioning near the high end suggests the market is pricing in continued positive fundamentals, though it also raises the risk of a pullback. Short-term momentum is accelerating sharply, with 1-month and 3-month price changes of +7.0% and +35.5%, respectively, compared to the S&P 500's +0.8% and +3.5%. The 3-month gain of 35.5% far exceeds the 1-year gain, indicating a recent acceleration that could signal a trend inflection or speculative froth. The relative strength index (RSI) is not provided, but the rapid advance suggests the stock may be entering overbought territory. Key support is at the 52-week low of $15.70, while resistance is at the 52-week high of $22.77. A breakout above $22.77 would signal further upside, while a breakdown below $15.70 would indicate a trend reversal. The stock's beta of 1.004 implies volatility roughly in line with the market, meaning it offers no diversification benefit in terms of volatility reduction.
Beta
1.00
1.00x market volatility
Max Drawdown
-18.5%
Largest decline past year
52-Week Range
$16-$23
Price range past year
Annual Return
+28.1%
Cumulative gain past year
| Period | DOC Return | S&P 500 |
|---|---|---|
| 1m | +3.1% | -0.7% |
| 3m | +34.3% | +2.9% |
| 6m | +28.0% | +7.2% |
| 1y | +28.1% | +16.9% |
| ytd | +36.2% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOC Fundamental Analysis
Revenue has been growing steadily, with Q1 2026 revenue of $753 million, up 7.1% year-over-year from $703 million in Q1 2025. The multi-quarter trend shows consistent sequential growth from $694 million in Q2 2025 to $719 million in Q4 2025, indicating a healthy trajectory. Revenue is driven by three segments: Lab ($213 million), Outpatient Medical Buildings ($318 million), and Senior Housing ($200 million), with Medical Buildings being the largest contributor. The 7.1% YoY growth is solid for a healthcare REIT and supports the investment case for stable cash flows. Profitability has improved markedly, with net income of $194 million in Q1 2026 versus $43 million in Q1 2025, a 352% increase. Gross margin turned negative at -20.0% in Q1 2026 due to a large cost of revenue, but operating margin was a healthy 15.5%, and net margin reached 25.7%, up from 6.1% a year ago. The company is clearly profitable and margins are expanding, which is positive for the investment thesis. The balance sheet is moderately leveraged, with a debt-to-equity ratio of 1.39 and a current ratio of 1.09, indicating adequate liquidity. Free cash flow (FCF) was $237 million in Q1 2026, up from $279 million in Q1 2025, and the FCF yield (FCF/market cap) is approximately 2.1%. ROE is low at 0.95%, typical for REITs due to high asset bases, but the company generates sufficient cash to cover its dividend, with a payout ratio of 11.9 (based on FCF) or 1.09 (based on net income). Overall, financial health is stable with manageable debt.
Quarterly Revenue
$752952000.0B
2026-03
Revenue YoY Growth
+7.1%
YoY Comparison
Gross Margin
-20.0%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOC Overvalued?
Since net income is positive, we use the P/E ratio as the primary valuation metric. The trailing P/E is 160.8x, while the forward P/E is -148.5x (negative due to estimated negative EPS), which is unusual and suggests the market expects a temporary earnings dip. The gap between trailing and forward P/E implies high uncertainty in near-term earnings. Compared to the industry average (not provided), the stock's P/E of 160.8x appears extremely high, but this is typical for REITs which often trade on FFO rather than GAAP earnings. The P/S ratio of 3.97x is more reasonable and may be a better comparison. Historically, the trailing P/E has ranged from 8.7x (Q3 2022) to 804x (Q4 2024), so the current 160.8x is elevated but not at the extreme high. The P/B ratio of 1.49x is near the lower end of its historical range (1.25x to 2.99x), suggesting the stock is not overvalued on a book value basis. Overall, the valuation appears stretched on earnings but reasonable on sales and book value, reflecting the market's optimism about future growth.
PE
160.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~96x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Healthpeak's debt-to-equity ratio of 1.39 and interest expense of $87.3M in Q1 2026 (74.6% of operating income) expose it to rising interest rates. The negative gross margin of -20.0% in Q1 2026 is a red flag, though operating margin remains healthy at 15.5%. The company's net income is volatile, swinging from a loss of $117M in Q3 2025 to a profit of $194M in Q1 2026, indicating earnings unpredictability. Free cash flow of $237M in Q1 2026 is strong, but the payout ratio of 11.9x (based on FCF) suggests the dividend is well-covered.
Market & Competitive Risks: The stock's beta of 1.004 implies market-like volatility, offering no diversification benefit. The trailing P/E of 160.8x is extremely high relative to historical levels (range 8.7x-804x), suggesting valuation compression risk if growth disappoints. The wide analyst target spread ($17-$29) reflects high uncertainty, and the recent Barclays downgrade from Overweight to Equal Weight signals caution. As a healthcare REIT, the stock is sensitive to interest rate changes and healthcare policy shifts.
Worst-Case Scenario: A combination of rising interest rates, occupancy declines in senior housing, and a recession could pressure earnings and lead to multiple compression. In such a scenario, the stock could fall to the 52-week low of $15.70, representing a 29.5% decline from the current price of $22.27. This would align with the analyst low target of $17.00, implying a 23.7% downside. The historical max drawdown of -18.53% provides a reference for potential losses.